3SOF

Quote from: Terliso on February 12, 2007, 01:34:13 PM

Quote from: jorgegr on February 09, 2007, 06:10:11 PM
Yes you are right, but I would like to see a little more volume before
getting in.

Now, we got more volume, are you IN?

Bought @ 4,25 - good luck to all

Deleted

Sell the news?! 


SIGA Begins Second Human Safety Trial of Its Lead Smallpox Drug
Tuesday February 13, 2:45 pm ET

NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA - News) announced today the launch of a 21-day, escalating, multiple-dose, Phase 1 safety, tolerability and pharmacokinetics human trial of SIGA-246, its lead smallpox drug. The study will examine the safety and pharmacokinetics of SIGA-246 at three different dosages in healthy volunteers when taken once a day for 21 days.

"This is one more milestone in the path to FDA approval," said Dr. Dennis E. Hruby, Chief Scientific Officer of SIGA. "This important study we believe will confirm the safety findings of an earlier human study and establish the likely human dose of SIGA-246."

The trial is being conducted at the Orlando Clinical Research Center in Orlando, FL, and is overseen by Dr. Thomas Marbury in collaboration with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The study is a double-blind, randomized, placebo-controlled, ascending multiple-dose study.

SIGA believes that SIGA-246 is the most advanced smallpox treatment currently in development. SIGA-246 represents a new approach to achieve a novel, orally active, antiviral therapeutic. It has already demonstrated significant antiviral activity in various animal trials, including the complete protection against human smallpox virus in primates as well as complete protection in two primate trials against high doses of monkeypox.

This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600014C.

http://biz.yahoo.com/bw/070213/20070213006285.html?.v=1

On the verge of a major MA crossover.

Wow! Nice action again!

Quote from: wontfindaname on March 08, 2007, 04:19:46 PM
Wow! Nice action again!

I guess it was some short covering or maybe someone knows something, actually it doesn't matter, as long as we go up!

Still holding long and strong!

There have been some developments in the complaint filed by Pharmathene. The motion to stay discovery filed by Siga was granted. This info is available in LexisNexis file and serve. Also, a lot of promising developments on the government front: Siga recently made a presentation to NIAID in which there was a hint that an emergency stockpile fund application may be made in Q1 2007. If that is granted, I see this stock going through the roof. We could see as much as 10 by then. Also, if the Pharmathene complaint is dismissed, we could see some M/A activity.

Quote from: wontfindaname on March 12, 2007, 11:31:15 AM
The motion to stay discovery filed by Siga was granted.

Hm, my English is not that great, what does it exactly mean? thx

Well, it's legal motion. Pharmathene filed a complaint against Siga. Siga filed a motion to dismiss the complaint. They also filed a motion to stay discovery, which means that they want Pharmathene to stop gathering any further evidence to support their complaint. That motion was granted. That is a very positive signal usually.

this news could be explosive for SIGA soon:  watch next week IMO

'US child in hospital after father has smallpox jab
The child has been treated with immune globulin, an antiviral drug called cidofovir, and an experimental antiviral made by Siga Technologies (SIGA.O: Quote, Profile , Research) called SIGA-246, Damon said.

"We are cautiously optimistic that the child is improving," Damon said.'

http://yahoo.reuters.com/news/articlehybrid.aspx?type=comktNews&storyID=urn:newsml:reuters.com:20070317:MTFH27966_2007-03-17_05-00-27_N16213321&pageNumber=1&imageid=&cap=&sz=&WTModLoc=HybArt-C1-ArticlePage1

This is indeed very positive news for Siga (and hopefully the child becomes better too). Unfortunately I'm going to be on vacation from tomorrow till the middle of the week. So I'll have to login to my brokerage from my phone to keep tabs on the stock price. I hope it doubles!!!

definitely has double potential shortterm and much more longterm

but that just my opinion

Great news!!!


Dad's smallpox shot infects son, 2
Experimental drugs bring Ind. boy back from brink of death

March 18, 2007
BY DAVE NEWBART Staff Reporter
A 2-year-old boy stricken with a rare infection from the smallpox vaccine is improving but remained in critical condition Saturday at the Comer Children's Hospital at the University of Chicago.

The boy was infected by his father, a U.S. soldier who was vaccinated in January in preparation for service in Iraq. But his deployment was delayed, and he returned home to Indiana late last month. His son, who suffers from skin lesions known as eczema, then became infected by vaccinia, a virus similar to smallpox and used in the vaccine against it.

The boy is the first person to suffer from the severe infection, known as eczema vaccinatum, since the U.S. military began inoculating troops in 2002. But his condition is so uncommon that U. of C. experts said they could not find reports of any cases in the United States since before 1972, when routine vaccinations for smallpox were halted.

Only seen in photos
"This is something that is new to us," said Kenneth Alexander, head of pediatric infectious disease at U. of C.

The boy, whose name was not released, was sent to U. of C. from a northwest Indiana hospital March 3 after he developed a severe rash. He didn't improve after treatment, and by March 7, a dermatologist noticed his lesions resembled those caused by smallpox -- something doctors had only seen in photos because the disease was eradicated.

Doctors contacted the federal Centers for Disease Control and Prevention, which agreed to fly in a treatment never used on a child, vaccinia immune globulin (VIG). The drug was hand-delivered by U.S. marshals.

The boy's condition continued to worsen, and last weekend, his lungs and kidneys began to fail. "He was near death," said Madelyn Kahana, chief of pediatric critical care medicine. Painful skin lesions covered most of his body.

'He is slowly improving'
The CDC then asked the Food and Drug Administration to grant emergency permission to try ST-246, an experimental drug being developed to fight smallpox. It had been effective in treating mice and monkeys infected with the virus, said U. of C. pediatrician John Marcinak, who is spearheading the boy's treatment. But it had never been used on a sick person.

That, combined with VIG and another drug, seems to be working. Since he first got the drug March 11, "he is slowly improving," Marcinak said.

The boy's mother contracted a milder form of the vaccinia virus from the boy and has been quarantined in the boy's room but is recovering well, officials said.

She has cried some days but in general has been "very strong and optimistic," said Surabhi Vora, a U. of C. fellow who has been assisting in the boy's treatment.

'Military has to be careful'
Doctors said the father -- who has since returned from his deployment at the hospital's urging -- had no idea he should stay away from his son after receiving the vaccine.

Kahana said the "military has to be careful" in making sure soldiers understand the risks and that they stay away from high-risk populations, such as people with eczema.

"They are trying to figure out where the misstep was," she said of the military. A military spokesman could not be reached Saturday.

The boy has two siblings, but no one else appears to have been infected, doctors said. The hospital has taken extreme precautions in treating the boy -- including keeping him in a room where the air only flows inward. Officials say the general public is not at risk because the infection is only transmitted through close physical contact.

Now doctors are just hoping the boy will make a full recovery. Before the infection worsened, the boy was fairly cooperative and talkative, saying "cup, cup, cup" when he was thirsty, Vora recalled. But since then, the boy has been sedated and is on a ventilator.

"I'm looking forward to seeing him awake and talking," she said.

http://www.suntimes.com/news/metro/302333,CST-NWS-VACCINE18.article

HALTED gonna gap and run
this trial by fire is better than a pr

Of course I didn't buy this but I wonder after this gaps up, if waiting for a bit to see if this will be a good entry point within the first hour...maybe too big of a gap to buy in.